Volcano Adds CardioSpectra High-Res Imaging To Intravascular Portfolio
This article was originally published in The Gray Sheet
Executive Summary
Intravascular imaging firm Volcano hopes to have an application before FDA for optical coherence tomography sometime next year after inking a deal worth up to $63 million to acquire the technology developer CardioSpectra
You may also be interested in...
Volcano Adds ‘Forward-Looking’ IVUS To Interventional Imaging Suite
Volcano expects to add Novelis' forward-looking intravascular ultrasound (FLIVUS) to the tools available with its s5i intravascular imaging system by the end of 2009
Volcano Adds ‘Forward-Looking’ IVUS To Interventional Imaging Suite
Volcano expects to add Novelis' forward-looking intravascular ultrasound (FLIVUS) to the tools available with its s5i intravascular imaging system by the end of 2009
InfraReDx Launches LipiScan To Evaluate Coronary Plaque
InfraReDx is launching its catheter-based LipiScan coronary imaging system, which relies upon near-infrared spectroscopy to identify plaque most likely to cause heart attacks and death, following April 25 FDA 510(k) clearance of the device